Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04083898 | Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma | terminated | Phase 1 | 15 | Washington University School of MedicineOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT04793399 | Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients | terminated | Phase 1 / Phase 2 | 9 | Fundacion Espanola para la Curacion de la Leucemia Mieloide CronicaOTHER | 1 | Mar 19, 2024 |
| clinicaltrials |
| NCT03473496 | CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma(MM) | terminated | N/A | 2 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT02451111 | Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma | terminated | Phase 2 | 190 | Swiss Cancer InstituteOTHER | 6 | Mar 13, 2024 | clinicaltrials |
| NCT02700841 | Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation | terminated | Phase 2 | 8 | University of NebraskaOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03151057 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | terminated | Phase 1 | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06160609 | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM | terminated | Phase 1 / Phase 2 | 9 | GlaxoSmithKlineINDUSTRY | 3 | Mar 12, 2024 | clinicaltrials |
| NCT02282358 | Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04968860 | Oral Health Condition and Quality of Life in Children With Leukemia | terminated | — | 9 | Paulo Sergio da Silva SantosOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04144140 | Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | terminated | Phase 1 | 24 | Eisai Inc.INDUSTRY | 5 | Mar 7, 2024 | clinicaltrials |
| NCT04509466 | Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL | terminated | Phase 1 / Phase 2 | 41 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT04548700 | Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL | terminated | Phase 1 | 38 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04920383 | ALPN-202 With PD-1 Inhibition in Advanced Malignancies(NEON-2) | terminated | Phase 1 | 29 | Alpine Immune Sciences, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT05345938 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 1 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03357224 | PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)(PARCT) | terminated | Phase 2 | 26 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Feb 22, 2024 | clinicaltrials |
| NCT05611853 | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | terminated | Phase 1 / Phase 2 | 9 | BioNova Pharmaceuticals (Shanghai) LTD.INDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT02841540 | A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes(Encore-MDS) | terminated | Phase 1 | 127 | Hemavant Sciences GmbHINDUSTRY | 7 | Feb 14, 2024 | clinicaltrials |
| NCT02508324 | IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia | terminated | Phase 2 | 43 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04956042 | Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 18 | CicloMed LLCINDUSTRY | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05641324 | A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) | terminated | Phase 1 | 4 | Anaveon AGINDUSTRY | 5 | Feb 12, 2024 | clinicaltrials |
| NCT04912427 | Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease | terminated | Phase 1 | 1 | Washington University School of MedicineOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT00277056 | Dysregulated Tyrosine Kinase Signaling in Leukemia | terminated | — | 30 | University of New MexicoOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03684694 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | terminated | Phase 1 / Phase 2 | 136 | ADC Therapeutics S.A.INDUSTRY | 6 | Feb 6, 2024 | clinicaltrials |
| NCT01186328 | EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 1 | 6 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Feb 1, 2024 | clinicaltrials |
| NCT03110354 | DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) | terminated | Phase 1 | 28 | Daiichi SankyoINDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | terminated | Phase 1 | 21 | Prelude TherapeuticsINDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02152956 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)(VOYAGE) | terminated | Phase 1 / Phase 2 | 244 | MacroGenicsINDUSTRY | 8 | Jan 30, 2024 | clinicaltrials |
| NCT03151811 | A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide(OCEAN) | terminated | Phase 3 | 495 | Oncopeptides ABINDUSTRY | 21 | Jan 30, 2024 | clinicaltrials |
| NCT04609579 | Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma | terminated | Phase 1 | 27 | Stingthera, Inc.INDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT00630565 | Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia | terminated | Phase 2 / Phase 3 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04092179 | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | terminated | Phase 1 / Phase 2 | 27 | University Health Network, TorontoOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04465760 | Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy | terminated | Phase 2 | 9 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT02031419 | Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma | terminated | Phase 1 | 174 | CelgeneINDUSTRY | 4 | Jan 18, 2024 | clinicaltrials |
| NCT01898793 | Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | terminated | Phase 1 / Phase 2 | 89 | Washington University School of MedicineOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03495713 | Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS | terminated | Phase 2 | 7 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT04785547 | ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT | terminated | Phase 2 | 3 | Prof. Christina PetersOTHER | 10 | Jan 16, 2024 | clinicaltrials |
| NCT02580981 | Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses | terminated | N/A | 21 | New Mexico Cancer Research AllianceOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT03138499 | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,(CheckMate 812) | terminated | Phase 3 | 23 | Bristol-Myers SquibbINDUSTRY | 3 | Jan 10, 2024 | clinicaltrials |
| NCT03502577 | BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma | terminated | Phase 1 | 19 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT03972943 | CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia | terminated | Early Phase 1 | 8 | University of UtahOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT03657251 | MMRF CureCloud Research Initiative | terminated | — | 1,105 | Multiple Myeloma Research FoundationOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT03864419 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda | terminated | Phase 1 | 18 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT04196010 | Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms | terminated | Phase 1 | 13 | University of WashingtonOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT05066165 | Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | Intellia TherapeuticsINDUSTRY | 2 | Dec 28, 2023 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 19, 2024source: clinicaltrials